Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:DAWN NASDAQ:IMVT NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.490.0%$38.57$25.83▼$83.63$8.81B0.235.47 million shs17.89 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIMVTImmunovant$40.31+0.5%$33.12$14.32▼$40.77$8.23B0.761.57 million shs1.17 million shsPCVXVaxcyte$58.71-3.2%$52.14$29.08▼$65.00$8.76B1.221.86 million shs1.63 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-0.05%+115.85%+149.37%+110.67%+184.27%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%+0.23%+225.72%IMVTImmunovant+0.55%+5.69%+30.88%+57.15%+138.66%PCVXVaxcyte-3.23%+4.69%+26.72%-4.83%+75.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.490.0%$38.57$25.83▼$83.63$8.81B0.235.47 million shs17.89 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIMVTImmunovant$40.31+0.5%$33.12$14.32▼$40.77$8.23B0.761.57 million shs1.17 million shsPCVXVaxcyte$58.71-3.2%$52.14$29.08▼$65.00$8.76B1.221.86 million shs1.63 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-0.05%+115.85%+149.37%+110.67%+184.27%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%+0.23%+225.72%IMVTImmunovant+0.55%+5.69%+30.88%+57.15%+138.66%PCVXVaxcyte-3.23%+4.69%+26.72%-4.83%+75.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.38Hold$78.27-6.25% DownsideDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideIMVTImmunovant 2.45Hold$39.70-1.51% DownsidePCVXVaxcyte 2.63Moderate Buy$86.0046.48% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, CRNX, PCVX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/7/2026CRNXCrinetics Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.007/7/2026CRNXCrinetics Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$55.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform7/7/2026CRNXCrinetics Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$62.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$81.00 ➝ $85.007/7/2026CRNXCrinetics Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold7/6/2026IMVTImmunovant Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026PCVXVaxcyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$7.70M1,143.27N/AN/A$9.71 per share8.60DAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01IMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)DAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)Latest DAWN, CRNX, PCVX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026PCVXVaxcyte-$2.0556N/AN/AN/A$12.50 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.87 millionN/A5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56DAWNDay One BiopharmaceuticalsN/A8.027.91IMVTImmunovantN/A9.099.09PCVXVaxcyteN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%DAWNDay One Biopharmaceuticals87.95%IMVTImmunovant47.08%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%DAWNDay One Biopharmaceuticals6.20%IMVTImmunovant1.80%PCVXVaxcyte3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableIMVTImmunovant120205.31 million201.61 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionableDAWN, CRNX, PCVX, and IMVT HeadlinesRecent News About These CompaniesVaxcyte to Participate in Upcoming Investor ConferencesJuly 8 at 4:05 PM | globenewswire.comVaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 2,250 Shares of StockJuly 7 at 9:38 AM | americanbankingnews.comJim Wassil Sells 2,250 Shares of Vaxcyte (NASDAQ:PCVX) StockJuly 7 at 9:36 AM | insidertrades.comAndrew Guggenhime Sells 10,000 Shares of Vaxcyte (NASDAQ:PCVX) StockJuly 7 at 8:38 AM | americanbankingnews.comVaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy NowJuly 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Has $40.70 Million Stock Holdings in Vaxcyte, Inc. $PCVXJuly 1, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)June 27, 2026 | theglobeandmail.comVaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 25, 2026 | finance.yahoo.comVaxcyte Announces Board Transition and New Director AppointmentJune 23, 2026 | tipranks.comVaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing VaccineJune 22, 2026 | insidermonkey.comVaxcyte (PCVX) Has a New Rating from Mizuho SecuritiesJune 20, 2026 | theglobeandmail.comSeven Fleet Capital Management LP Buys New Position in Vaxcyte, Inc. $PCVXJune 19, 2026 | marketbeat.comVaxcyte, Inc. $PCVX Shares Acquired by T. Rowe Price Investment Management Inc.June 19, 2026 | marketbeat.comEcoR1 Capital LLC Purchases Shares of 450,000 Vaxcyte, Inc. $PCVXJune 18, 2026 | marketbeat.comElmind Capital LP Makes New Investment in Vaxcyte, Inc. $PCVXJune 18, 2026 | marketbeat.comVaxcyte, Inc. $PCVX Shares Sold by Eversept Partners LPJune 18, 2026 | marketbeat.comCormorant Asset Management LP Reduces Stake in Vaxcyte, Inc. $PCVXJune 18, 2026 | marketbeat.comVaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 StudyJune 17, 2026 | finance.yahoo.comSpruce Street Capital LP Takes Position in Vaxcyte, Inc. $PCVXJune 16, 2026 | marketbeat.comBrown Advisory Inc. Sells 110,060 Shares of Vaxcyte, Inc. $PCVXJune 16, 2026 | marketbeat.comNEXTBio Capital Management LP Makes New $4.41 Million Investment in Vaxcyte, Inc. $PCVXJune 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026DAWN, CRNX, PCVX, and IMVT Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$83.49 -0.04 (-0.05%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$83.45 -0.04 (-0.05%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Immunovant NASDAQ:IMVT$40.31 +0.22 (+0.55%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$40.30 -0.01 (-0.02%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Vaxcyte NASDAQ:PCVX$58.71 -1.96 (-3.23%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$60.05 +1.34 (+2.29%) As of 04:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
